1008 completed, 327 terminated, 219 recruiting, 166 unknown. 2015 Phase 2, 485 Phase 1, 62 Phase 3.
Follow Bone Marrow Diseases: new trials by email Literature Review of Bone Marrow Diseases trials Research Report on Bone Marrow Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sonrotoclax in Combination With Azacitidine for Previously Untreated Higher-risk Myelodysplastic Syndromes Each treatment cycle is 28-days. Azacitidine 75 mg/m² is administered subcutaneously or intravenously on Days 1-7 of each cycle. Sonrotoclax is orally administered once daily on Days 1-14 within each - MDS (Myelodysplastic Syndrome) | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 10 | 2028-09-01 | 2026-11-12 |
| Prenatal Transplantation for Fetuses With Fanconi Anemia IUHSCT for FA-affected fetuses - Fanconi Anemia, Anemia, Hypoplastic, Congenital | Phase 1 / Phase 2 | Not yet recruiting | Agnieszka Czechowicz | 12 | 2028-01-01 | 2026-06-16 |
| Conditioning Regimen Containing Low-Dose ATG for the Treatment of AA Receiving sUCBT Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®) - Aplastic Anaemia | Phase 2 | Not yet recruiting | Anhui Provincial Hospital | 59 | 2027-08-01 | 2026-10-21 |
| A Study of Rusfertide in Adults With Polycythemia Vera in China Rusfertide - Polycythemia Vera | Phase 2 | Not yet recruiting | Takeda | 24 | 2027-03-01 | 2026-08-28 |
| Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 2 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 35 | 2027-01-30 | 2026-11-05 |
| A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) BLEX 404 Oral Liquid - Myelodysplastic Syndrome (MDS) | Phase 2 | Not yet recruiting | BioLite, Inc. | 52 | 2027-01-01 | 2026-04-13 |
| Asciminib Frontline Risk Adapted Dasatinib 80mg QD (5 days per week), Standarc of Care - Chronic Myeloid Leukemia (CML) | Phase 2 | Not yet recruiting | Prof. Dr. med. Andreas Hochhaus | 200 | 2027-01-01 | 2026-09-04 |
| Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms Oral THU-decitabine - Myelofibrosis, MPN - Accelerated or Blast Phase | Phase 2 | Not yet recruiting | John Mascarenhas | 20 | 2027-01-01 | 2026-10-14 |
| Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris NM8074, Soliris - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 12 | 2027-01-01 | 2026-04-13 |
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS) Allogeneic umbilical cord mesenchymal stem cells, Decitabine - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Suspended | Sclnow Biotechnology Co., Ltd. | 40 | 2026-12-31 | 2026-04-23 |
| A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration, Emavusertib - Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 270 | 2026-12-18 | 2026-09-22 |
| CK0801 for Treatment of Aplastic Anemia CK0801 - Aplastic Anemia | Phase 2 | Not yet recruiting | Cellenkos, Inc. | 12 | 2026-12-03 | 2026-10-20 |
| A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant Maintenance Therapy, No intervention - Myeloid Disorders, Myelodysplastic Syndromes | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 450 | 2026-12-01 | 2026-10-13 |
| Revumenib in Patients With Myelofibrosis Revumenib, Ruxolitinib, FEDRATINIB - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 1 / Phase 2 | Not yet recruiting | John Mascarenhas | 32 | 2026-12-01 | 2026-07-29 |
| Study of Allogeneic Stem Cell Transplant in Myelodysplastic Syndrome Following Conditioning With Fludarabine and Total Body Irradiation 800 cGy Allogeneic Stem Cell Transplant - MDS, Myelodysplastic Syndrome MDS | Phase 2 | Not yet recruiting | Ronald Paquette | 20 | 2026-12-01 | 2026-10-28 |
| Study of LusPACercept in Participants With Myelofibrosis Associated Anemia and Thrombocytopenia Luspatercept, Pacritinib - Myelofibrosis | Phase 2 | Not yet recruiting | Case Comprehensive Cancer Center | 50 | 2026-12-01 | 2026-11-13 |
| Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 132 | 2026-11-27 | 2026-09-09 |
| Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms pacritinib - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 160 | 2026-11-18 | 2026-11-13 |
| Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-11-05 | 2026-10-08 |
Showing 20 of 2015. Sign in to see all of them.
Myelodysplastic Syndromes (1007) · Leukemia, Myeloid, Acute (716) · Leukemia (462) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (404) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (370) · Myeloproliferative Disorders (284) · Primary Myelofibrosis (280) · Leukemia, Myelomonocytic, Chronic (264) · Lymphoma, Non-Hodgkin (226) · Leukemia, Myeloid, Chronic-Phase (210) · Hodgkin Disease (200) · Multiple Myeloma (194) · Leukemia, Lymphocytic, Chronic, B-Cell (193) · Anemia, Aplastic (183) · Anemia, Refractory, with Excess of Blasts (179)
Hemic and Lymphatic Diseases (2014) · Hematologic Diseases (1962) · Neoplasms (1338) · Neoplasms by Histologic Type (1275) · Leukemia, Myeloid (1124) · Pathological Conditions, Signs and Symptoms (872) · Pathologic Processes (861) · Disease Attributes (839) · Chronic Disease (803) · Leukemia (788) · Myeloproliferative Disorders (736) · Immune System Diseases (558) · Immunoproliferative Disorders (508) · Lymphatic Diseases (500)
Cyclophosphamide (252) · fludarabine phosphate (206) · Busulfan (168) · fludarabine (168) · Azacitidine (161) · Cytarabine (142) · Mycophenolic Acid (142) · Cyclosporine (141) · Tacrolimus (140) · Whole-Body Irradiation (139) · Peripheral Blood Stem Cell Transplantation (128) · Antilymphocyte Serum (124) · Filgrastim (105) · Decitabine (92) · Melphalan (91)
M.D. Anderson Cancer Center (194) · Fred Hutchinson Cancer Center (104) · National Cancer Institute (NCI) (76) · Novartis Pharmaceuticals (59) · National Heart, Lung, and Blood Institute (NHLBI) (52) · Memorial Sloan Kettering Cancer Center (50) · Masonic Cancer Center, University of Minnesota (46) · Groupe Francophone des Myelodysplasies (29) · City of Hope Medical Center (23) · H. Lee Moffitt Cancer Center and Research Institute (23) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (23) · Case Comprehensive Cancer Center (21) · Incyte Corporation (20) · Institute of Hematology & Blood Diseases Hospital, China (20) · Bristol-Myers Squibb (19)
United States (1329) · France (184) · Italy (179) · Germany (178) · China (144) · United Kingdom (142) · Canada (129) · Spain (117) · South Korea (89) · Australia (81) · Belgium (65) · Netherlands (54) · Japan (50) · Poland (48) · Israel (46)
Jorge Cortes, MD (15) · Guillermo Garcia-Manero, MD (14) · Brenda Sandmaier (12) · John Mascarenhas, MD (11) · Guillermo Garcia-Manero (7) · Neal S Young, M.D. (7) · Alessandro Rambaldi, MD (6) · Courtney DiNardo, MD (6) · Elias Jabbour, MD (6) · Jorge E Cortes, MD (6)
PMID 32499241, PMID 34724566, PMID 23524640, PMID 28835440, PMID 29674506, PMID 30885996, PMID 23065508, PMID 23620574, PMID 29958797, PMID 21403127, PMID 22430088, PMID 25310303, PMID 25361995, PMID 27658437, PMID 35007144, PMID 35235189, PMID 35982483, PMID 40073835, PMID 41758981, PMID 17715389, PMID 18997171, PMID 19179301, PMID 20685256, PMID 22055111, PMID 22067384, PMID 22133778, PMID 24383844, PMID 25527568, PMID 25824692, PMID 27400247, PMID 28870615, PMID 29419434, PMID 30992268, PMID 31217161, PMID 31527168, PMID 32343796, PMID 35998303, PMID 36054756, PMID 40313042, PMID 40593138, PMID 41124654, PMID 42013378, PMID 42749863, PMID 10204198, PMID 10499616, PMID 1090310, PMID 11054091, PMID 11071652, PMID 11222401, PMID 11331327
P30CA015704 (42), P01CA018029 (16), P30CA006973 (16), 2017 (13), 2018 (13), 2023 (13), P30CA043703 (13), P30CA033572 (12), 2015 (11), 2016 (11), P30CA016672 (11), P01CA078902 (10), P01CA108671 (10), U10CA032102 (10), 2014 (9)